Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
Taltz® (ixekizumab): Can Ixekizumab be used in Patients with COVID-19 (Coronavirus disease 2019)?
At this time, Lilly has not studied the use of ixekizumab in patients with COVID-19 nor in patients at risk of contracting COVID-19.
At this time, Lilly has not studied the use of ixekizumab in patients with coronavirus disease 2019 (COVID-19).
Ixekizumab should not be used during active COVID-19 infection and may be resumed after medical consultation and infection is resolved.1
If COVID-19 is confirmed, ixekizumab should be immediately discontinued and may be resumed after medical consultation and infection is resolved.1
If COVID-19 infection is suspected and signs and symptoms of acute infection occur, the patient should consult with their healthcare provider and seek medical advice for guidance on continuing and initiating ixekizumab treatment.1
For current NICE guidance, please refer to 'COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders' www.nice.org.uk/guidance/ng167.
Use of Ixekizumab in High Risk Areas
At this time, Lilly has not studied the use of ixekizumab in patients at risk of contracting COVID-19.
COVID-19 is an active respiratory infection, which is typically mild and may also lead to acute respiratory distress syndrome which can be lethal.1
Infectious Disease Resources
For the most current information regarding COVID-19 and Coronavirus, please refer to the websites of local health authorities and/or WHO at WHO Coronavirus disease (COVID-19) outbreak.
Ixekizumab Infection-Related Warnings and Precautions according to the SmPC
Ixekizumab is contraindicated in patients with clinically important active infections (e. g. active tuberculosis).2
Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.2
Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur. If an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.2
Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2
Ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.2
Ixekizumab is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.2
Ixekizumab is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).2
Lilly = Eli Lilly and Company
WHO = World Health Organization
Date of Last Review: February 25, 2020